Sixty nine patients with chronic duodenal or juxtapyloric ulceration were studied in a prospective double blind randomised trial to compare the efficacy of antacid and placebo at high (30 ml seven times daily) and low (10 ml as required) doses. After four weeks ulcers had healed in 12 out of 18 patients (67%) receiving "low dose" antacid compared with in six out of 17 patients (35%) receiving low dose placebo; ulcers had also healed in six out of 19 patients (32%) receiving "high dose" antacid compared with in two out of 15 patients (13%) receiving high dose placebo. Overall, the effect of antacid was superior to that of placebo in healing ulcers (p<0 05) and the effect of low dose treatment was superior to that ofhigh dose treatment (p <0 01). There were no significant differences between antacid and placebo at eight weeks. Antacid was better than placebo in relieving pain, but the difference was not significant. Poor compliance and high incidence of diarrhoea made high dose antacid an impractical treatment. Low dose antacid was associated with a significantly better rate of healing than high dose antacid and was far better tolerated.
Introduction
In Great Britain an estimated £30 000 000 is spent annually on antacids, for which over 50 formulations are listed in Mims. Although the lay public and medical practitioners traditionally accept that these compounds have beneficial therapeutic effects, the evidence is controversial. ' Patients randomised to treatment with antacid at a high dose were expected to consume 2940 ml of the drug each fortnight (98 doses), but in every case they consumed considerably less of the drug than the equivalent placebo group and even the placebo groups consumed less than expected by roughly 1000 ml/fortnight (33 doses) (table IV) . (table III) . Even in patients receiving placebo ulcer pain tended to diminish relative to time, but, as shown by others,9 there was unequivocal evidence of a rapid placebo related effect during single episodes of pain. Our placebo contained a silicone polymer that, although having no neutralising capacity, might have contributed to the relief of dyspeptic symptoms by virtue of its antifoaming or antiflatulant activity. We tried, however, to record only characteristic ulcer pain, against which our placebo was considered to be inert. Inadequate relief from pain was severe enough to precipitate dropout or withdrawal from the trial only in patients receiving placebo, and paracetamol, prescribed as an alternative treatment, did not appear to represent a satisfactory substitute for antacid in these instances.
Our patients did not find acceptable the intensive high dose regimens advocated in the USA.'0 1' Despite our enthusiastic attempts at persuasion, patient compliance was as problematical as described by Roth and Berger."' The median volume of high dose placebo consumed was only about two thirds the desired amount (table IV) . Significantly less high dose antacid was taken than had been recommended, and several patients either dropped out or refused to continue treatment because of diarrhoea despite adjustments in dose and our choice of a trial antacid containing aluminium hydroxide. The low dose antacid regimen was far better tolerated. Sixteen patients (87%) receiving low dose antacid completed the entire course of treatment compared with 12 (61%) of those receiving high dose antacid and 14 (82%) and 12 (80%) of those receiving low dose and high dose placebo respectively.
Thus this study has shown clearly, and for the first time, that the large doses of antacid advocated in the USA are poorly tolerated by patients in Liverpool; this might apply to the United Kingdom as a whole. Treatment with low doses (10 ml as required) of antacid can significantly enhance ulcer healing, and is superior to treatment with high doses of antacid and far better tolerated. The pain relieving effect of antacid was not significantly better than that of placebo. In trials of ulcer healing results must be interpreted with caution if self administration of antacids is permitted.
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Addendum
The X2 values were obtained as follows: if p is the estimated proportion of healing (P) Logit (p)=Log = + Ml + P +Y 1-p where i (compound)= 1, 2 (antacid, placebo), j (dose)= 1, 2 (low, high), Xu=grand mean, a=variable depending on compound, 3 =1, variable depending on dose, and y = interaction between compound and dose.
The X2 values are those corresponding to twice the improvement in log likelihood (corresponding to fitting a, 3, and y respectively, a statistic that has roughly a x2 distribution). The calculation was done using the Generalised Linear Interactive Modelling (GLIM) computer program.
